COPD Market Snapshot: New Products, Limited Differentiation
New drugs are hitting the COPD market, but largely offer incremental benefit over gold standards Advair and Spiriva. Given the modest efficacy improvement and increasingly price sensitive patients and payers, new higher-priced products may find the commercial market a challenge.
You may also be interested in...
FLAME Shoots LABA/LAMA Combos Up To First Choice In COPD
At the American Thoracic Society annual meeting, science committee chair says change in COPD treatment guidelines to favor LABA/LAMA as preferred option will be considered soon.
Novel COPD Exercise Claims Eluded Boehringer In Bid to Differentiate Striverdi
Sponsor’s claimed impact on exercise tolerance was not adequately supported and should not serve as a marketing advantage for the chronic obstructive pulmonary disease drug, FDA review staff said. However, Boehringer Ingelheim’s failed attempt for the exercise-related labeling language spurred the agency to clarify the types of studies and endpoints that potentially could support such claims.
Boehringer’s Striverdi Respimat Approved For COPD, But Without Exercise Claim
The long-acting beta agonist olodaterol cleared FDA for treatment of chronic obstructive pulmonary disease, but it didn’t gain the differentiating claim the German pharma was seeking.